Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of intravitreal remigromig EYE103 in adults with neovascular age-related macular degeneration NVAMD or macular edema following branch retinal vein occlusion BRVO. This randomized, dose-masked Phase 2 study includes four patient groups, comparing low and high doses of remigromig, alone or combined with aflibercept for certain participants. The study aims to assess safety and efficacy of these treatments for these eye conditions. Participants will receive three injections of remigromig into the study eye, spaced four weeks apart. In one group of incomplete responders with NVAMD, aflibercept injections are also given on the first day. Participants are randomized within four cohorts to receive either a low or high dose of remigromig, with some receiving combination therapy. Enrollment and treatment timing are managed by the study sponsor. Throughout the study, participants will return for safety and efficacy assessments at each injection visit and may have additional visits two weeks after injections depending on their group. Assessments include vision tests using the ETDRS chart, eye examinations, and imaging to measure retinal thickness. The main outcome measure is the change in best-corrected visual acuity at 12 weeks. The study concludes with a final visit at week 12, after which safety and effectiveness data will be reviewed.
Actively Recruiting
Researchers are studying the long-term safety and tolerability of JNJ-81201887, given as an injection into the eye, for people with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD. This extension study follows participants who took part in earlier parent studies to continue monitoring their health without new treatments given during this phase. The study aims to understand how participants respond over an extended period after the initial treatment. Participants who previously received either a low or high dose of JNJ-81201887, or a sham procedure, in earlier clinical trials will join this long-term extension study. No additional treatments or interventions will be provided during this study. The trial is designed to observe participants without administering further study drugs, focusing on those who were part of the parent studies identified by specific study codes. Throughout the study, participants will be monitored for up to 5 years. Assessments will include checking for any eye-related or systemic side effects, abnormalities in laboratory tests, retinal imaging, and eye examinations. Visual acuity changes will also be measured from baseline up to 42 months. Participants will provide informed consent and be regularly evaluated to track their health and visual function over time.
Actively Recruiting
Researchers are evaluating how well different doses of the medicine BI 3812465 are tolerated in adults with diabetic macular edema that affects the center of the eye. This is the first time BI 3812465 is given to humans. The study includes two parts an initial phase testing low, medium, and high doses sequentially, followed by a phase where more participants receive these doses in a randomized way to assess safety and tolerability. Participants receive BI 3812465 as injections into the back of the eye, with a total of three injections given during the study. In Part 1, a small group receives increasing doses starting from low, and in Part 2, a larger group is randomized to receive one of the three dose levels. The treatment period involves these injections, and dosing only advances if lower doses are tolerated. Participants stay in the study for up to 7 months, attending 19 visits to the study site or, when possible, having visits at their home. During these visits, doctors check the severity of the eye condition and monitor for any health problems related to the medicine. The study measures dose limiting events, ocular adverse events, and other safety outcomes throughout the treatment and follow-up period.
Actively Recruiting
Researchers are evaluating the similarity in effectiveness between ABP 938 8 mg and Aflibercept US 8 mg in people with neovascular age-related macular degeneration nAMD. The study aims to compare changes in best corrected visual acuity BCVA to understand how these treatments perform in improving vision for participants with this eye condition. Participants will be randomly assigned to receive intravitreal injections of either ABP 938 8 mg or Aflibercept 8 mg at the start of the study, Week 4, and Week 8. After these initial doses, participants will be regularly assessed starting at Week 16 to adjust injection schedules based on disease activity. The injections may then continue at intervals ranging from every 4 to 16 weeks up until the end of the study. Throughout the trial, participants will attend scheduled visits where vision tests like BCVA and imaging scans such as spectral-domain optical coherence tomography SD-OCT and fluorescein angiography FA will be performed. Researchers will monitor changes in vision, retinal fluid presence, lesion size, and safety outcomes including adverse events and immune responses. The study includes ongoing assessments of drug levels in blood samples, with participation lasting through multiple weeks with continuous monitoring.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a single intravitreal injection of 4D-150 compared to aflibercept in adults with neovascular age-related macular degeneration nAMD. This Phase 3 randomized, double-masked trial includes a primary global cohort with completed enrollment and an ongoing Japan cohort. The study aims to understand visual acuity changes and treatment needs over time in this patient population. Participants are randomly assigned to receive either one dose of 4D-150 administered as a single intravitreal injection on Day 1 or aflibercept injections at scheduled visits. The study follows participants for up to 104 weeks to assess the need for additional aflibercept injections after the initial treatment. The trial includes safety and efficacy monitoring with comparisons between the study drug and the active comparator. During the trial, participants will undergo regular eye exams including measurements of best corrected visual acuity BCVA at 52 weeks and up to 104 weeks. Central subfield thickness and other anatomical features will be monitored using imaging techniques such as fluorescein angiography and optical coherence tomography. Researchers will track injection frequency, visual function, and eye health. The total participation duration may span over two years with ongoing assessments to evaluate treatment outcomes and safety.